Strait Access Technologies (SAT) was founded in 2008 as a start-up company at the University of Cape Town. Our objective is the development of cost effective and enabling technologies to treat heart valve diseases. Our focus is primarily on creating intelligent surgical products to treat Rheumatic patients in emerging economies. Solving the complex technical challenges for devices required in younger Rheumatic candidates, has resulted in breakthrough solutions that have competitive advantages for older patients with degenerative heart valve conditions – in emerging and developed economies.
Specifically, our second generation balloon expandable TAVR valve for rheumatic and degenerative aortic valve disease is designed to treat the entire aortic valve disease spectrum from calcific aortic stenosis to pure aortic regurgitation in patients with non-calcified, compliant annuli.
SAT was founded by a small team of clinical and biomedical professionals operating at the interface of the Industrialised and the Developing World. The founders and a dedicated group of designers, engineers and chemists combine experience and expertise to create innovative medical devices for the heart.
Sadly, one of SAT’s founding partners and Technical Director, Professor Deon Bezuidenhout, died suddenly in April 2023. Prof. Bezuidenhout, the Head of Biomaterials Sciences at the Cardiovascular Research Unit of the University of Cape Town until his passing, had been intimately involved in the management of SAT, overseeing the technical aspects from R&D to production. (Please read his Obituary here.)